Reuters logo
BRIEF-Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients
September 26, 2017 / 11:18 AM / in a month

BRIEF-Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients

Sept 26 (Reuters) - Akebia Therapeutics Inc

* Akebia announces positive top-line results from phase 2 study of vadadustat in Japanese patients with non-dialysis-dependent chronic kidney disease

* Says ‍phase 3 study in Japan expected to commence by year-end 2017​

* Says co provides Mitsubishi Tanabe with option to access global phase 3 vadadustat data for payments of up to $25 million​

* Says ‍results confirm findings from previous studies of vadadustat​

* Akebia Therapeutics Inc says MTPC will be responsible for all costs associated with phase 3 vadadustat program in Japan

* Akebia Therapeutics Inc says expects to submit a Japanese New Drug Application (JNDA) for vadadustat with an anticipated launch in 2020. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below